Advertisement

Topics

Moderate-to-Severe Plaque Psoriasis - Biotech, Pharma and Life Science Channel

07:57 EDT 29th July 2017 | BioPortfolio

Psoriasis is a chronic, immune disease that affects the skin. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects up to 1.8 million people in the UK,ix approximately 20 percent of whom have moderate-to-severe plaque psoriasis.Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes and heart disease. The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.

News Articles [118 Associated News Articles listed on BioPortfolio]

Better Coping with Psoriasis in the Summer

WASHINGTON, July 27, 2017 /PRNewswire/ -- While many are welcoming the warmer season, those suffering from psoriasis may dread its return.  The very visible autoimmune disease, which commonly man...

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira®

RIDGEFIELD, Conn., July 27, 2017 /PRNewswire/ -- Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study ...

Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection

Dermatology Unit Is Rebranded Ortho Dermatologics LAVAL, Quebec, July 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the launch...

AnaptysBio Inc ANAB Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAnaptysBio Inc AnaptysBio is a biotechnology company that develops antibody drug candidates. The company's product pipeline comprises ANB020 and ANB019. It's ANB020 is a product candidate used ...

Dermatology Drugs Market Global Report 2017 Including: Antibacterial, AntiFungal, AntiViralCovering: Galderma Nestle Skin Health, Johnson Johnson, AbbVie, GlaxosmithKline, and Pfizer [Report Updated: 17072017] Prices from USD $4000

Dermatology drugs market include medications that are used for the treatment of skin conditions such as dermatitis including eczema, rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair lo...

Dermatological Drugs Market Forecast 2017-2027

LONDON, July 25, 2017 /PRNewswire/ -- Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johns...

Medical Marijuana, Inc. and Subsidiary HempMeds Brasil™ Garners Vast Media Coverage Across Brazil of Company and Cannabis Market Growth

SAN DIEGO, July 20, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that it and its subsidiary HempMeds...

LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union

BALLERUP, Denmark, July 20, 2017 /PRNewswire/ -- LEO Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a new biologic for the tre...

Chronic Plaque Psoriasis Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10072017] Prices from USD $5750

DelveInsight's Chronic Plaque Psoriasis Market Insights, Epidemiology and Market Forecast 2025 Reports provides an overview of the disease and global market size of the Chronic Plaque Psoriasis for ...

Amyotrophic Lateral Sclerosis (ALS) and Psoriasis Patients Receive Brazilian Government Permission to Be Treated with Medical Marijuana, Inc. Subsidiary, HempMeds® Brasil, Flagship Product RSHO™

SAN DIEGO, July 19, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA) is the first publicly traded cannabis company in the United States. Its subsidiary HempMeds® Brasil ...

Events [0 Results]

None

Companies [21 Associated Companies listed on BioPortfolio]

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

fOCUS Pharmaceuticals, LLC

fOCUS Pharmaceuticals is a privately held generic and branded pharmaceutical company specializing in the research and development of prescription dermatology products. Our primary focus are in the are...

Clinical Trials [546 Associated Clinical Trials listed on BioPortfolio]

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

This trial will investigate the safety, tolerability and pharmacokinetic (PK) data of LEO 32731 (and major human metabolite LEO 40815) in healthy male Japanese subjects. The primary object...

This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.

This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis, in the Portuguese National H

This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis

The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (aged greater than or equal to 12 years to less than 18 years inclusive) with moderate...

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.

MAP Study: Methotrexate and Adalimumab in Psoriasis

Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on comb...

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.

This Trial Compares BI 695501 and Humira® in Patients With a Long-term Disease That Causes Red, Scaly Patches on the Skin (Plaque Psoriasis). The Trial Looks at the Way the Body Takes up the Drugs and How Effective and Safe They Are

The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with m...

Study of the Efficacy and Safety of Topical P-3073 in the Treatment of Mild to Moderate Psoriatic Fingernail/s

The objective of this phase III study is to evaluate the efficacy, systemic safety and local tolerability of P-3073 (calcipotriene 0.005%) nail solution in patients with mild to moderate p...

PubMed Articles [344 Associated PubMed Articles listed on BioPortfolio]

HIV Infection Increases the Risk of Incident Psoriasis: A Nationwide Population-Based Cohort Study in Taiwan.

HIV can cause an imbalance of T lymphocytes, which may contribute to the onset of psoriasis. However, the association of HIV with incident psoriasis has not been extensively studied.

Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.

AbbVie provides a free-to-patient patient support program (PSP) to assist adalimumab-treated patients with medication costs, nurse support, injection training, pen disposal, and medication reminders. ...

Severe subcutaneous hematoma in a patient with psoriatic arthritis: Changes of platelet count in psoriatic patients with biologic agents.

The effectiveness of biologics has changed therapeutic strategies for psoriasis dramatically, but biologics are known to have various adverse effects. We report a 63-year-old woman with psoriatic arth...

Dimethyl fumarate modulates neutrophil extracellular trap formation in a glutathione and superoxide-dependent manner.

Neutrophil (polymorphonuclear) granulocytes (PMN) were shown to contribute to the pathogenesis of psoriasis by releasing IL-17 and LL-37/ DNA complexes via neutrophil extracellular traps (NET), webs o...

Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Rheumatoid arthritis and spondyloarthritis are inflammatory joint disorders with an autoimmune pathogenesis and systemic involvement. The skin is one of the most frequently affected extraarticular sit...

Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.

Patients with immune-mediated disorders such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and rheumatoid arthritis are increasingly treated with tumor necrosis factor (TNF) inhibit...

Psoriasis: a mixed autoimmune and autoinflammatory disease.

In recent years marked progress has been made in our understanding of the critical biologic and immunologic pathways involved in psoriasis. Genetic studies have demonstrated that susceptibility to pso...

Reporting of outcomes in randomised controlled trials on nail psoriasis; a Systematic Review.

Harmonization of outcome measures is needed to increase the value of clinical trials on nail psoriasis. To provide the first step in core outcome set (COS) development, a systematic review was conduct...

Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review.

Biologic therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. To investigat...

Changes in IL-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study.

Psoriasis vulgaris is an immune-mediated disease characterized by skin and systemic inflammation that is associated with an increased risk of comorbidities such as cardiovascular disease. Although typ...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Quick Search
Advertisement
 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

review and buy Moderate-to-Severe Plaque Psoriasis market research data and corporate reports here

Channels Quicklinks